How large is the vivotif market, and what is its growth trajectory?
The vivotif market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increasing international travel, rising prevalence of typhoid fever, rising urbanization, expanding healthcare access, and rising disposable income.
The vivotif market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to growing awareness about benefits of vaccination, increasing incidence of typhoid fever, convenience and effectiveness of oral vaccines, advancements of vaccine technology, and increase in research activities. Major trends in the forecast period include growing preference for oral vaccines, increased focus on travel vaccines, integration of vivotif into travel health kits, development of combination vaccines, and shift towards preventive healthcare.
Get Your Free Sample of The Global Vivotif Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20449&type=smp
What are the key forces behind the vivotif market’s growth in recent years?
The increasing incidence of typhoid fever is expected to propel the growth of the vivotif market going forward. Typhoid fever is a bacterial infection caused by Salmonella Typhi, which spreads through contaminated food or water and causes fever, abdominal pain, and fatigue. The increasing incidence of typhoid fever is due to poor sanitation, lack of access to clean water, and growing antibiotic resistance, particularly in low-income regions. Vivotif helps reduce typhoid fever incidence by providing a preventive oral vaccine against Salmonella Typhi, especially in regions with poor sanitation. For instance, in August 2024, according to reports published by GOV.UK, a UK-based government platform, in 2023, around 645 cases of typhoid fever were reported in England, Wales, and Northern Ireland, marking an increase from 470 cases in 2022, indicating a rise in the incidence of the disease year-over-year. Therefore, the increasing incidence of typhoid fever is driving the growth of the vivotif market.
What are the major segments of the vivotif market?
The vivotif market covered in this report is segmented –
1) By Clinical Indication: Typhoid; Other Indications
2) By Distribution Channel: Direct Sales; Online Pharmacies; Retail Pharmacies
3) By End-User: Adults; Pediatric
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/vivotif-global-market-report
Which companies dominate the vivotif market?
Major companies operating in the vivotif market are Bavarian Nordic A/S
What major trends will shape the vivotif market during the forecast period?
What are the key regional dynamics of the vivotif market, and which region leads in market share?
Asia-Pacific was the largest region in the vivotif market in 2024. The regions covered in the vivotif market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Vivotif Market Report 2025 Offer?
The vivotif market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Vivotif is an oral vaccine for preventing typhoid fever, a potentially life-threatening illness caused by the bacterium Salmonella typhi. It is approved for use in adults and children over 6 years of age. It is advised for those at higher risk, such as travelers to endemic areas, individuals with intimate exposure to S. typhi carriers, and microbiology laboratorians working frequently with S. typhi.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20449
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
